Venture-backed Milestone seeks up to $115 mln in Nasdaq IPO
Montréal-based cardiovascular drug maker Milestone Pharmaceuticals has filed a preliminary prospectus with the U.S. Securities Exchange Commission for an initial public offering. The company is seeking up to $115 million (US$86 million) from an offering of common shares on the Nasdaq Global Market, the filing said. It intends to list under the symbol MIST. Founded in 2005, Milestone is the developer of etripamil, a nasal spray formulation of calcium channel blockers used to terminate episodes of transient cardiovascular conditions. Milestone has raised roughly $220 million in venture capital financing. This includes $105 million raised last year, led by RTW Investments .
15 April 2019•1 min read
